To review the newest research about the effects of combination antiretroviral therapy (cART) on cancer risk.
INTRODUCTION
HIVþ persons are at increased risk of cancer when compared with the general population. This risk seems to be higher for malignancies driven by viral and bacterial coinfections [1] [2] [3] [4] [5] [6] [7] [8] 9 && ], although HIVþ persons also have excess risk of infection-unrelated malignancies [10] . The question as to how combination antiretroviral therapy (cART) influences cancer risk has been debated since the beginning of the AIDS epidemics. During HIV infection, cancer risk seems to be determined by a complex interaction between prolonged life expectancy [1] , traditional risk factors [11] [12] , pro-oncogenic viruses coinfection, potentially direct oncogenic effects of HIV [13] [14] [15] , cART toxicity [16,17 && 
,18
& ] and activated inflammation and coagulation [19] [20] [21] [22] [23] . It is thus difficult to disentangle the direct effect of cART on cancer risk from other factors postulated to play a role in carcinogenesis.
Since cART became available in the late-1990s, Kaposi sarcoma and non-Hodgkin lymphoma (NHL) have been the two malignancies that experienced the greatest decline in incidence [24] [25] [26] [27] . At that time, cART was usually initiated late in the course of HIV infection when CD4 þ cell counts dropped below a given threshold [28, 29] . Because cART improves immune function by suppressing viral replication, the reduced incidence of Kaposi sarcoma and NHL was considered as evidence to link immunosuppression to cancer development during HIV infection. This view was reinforced by reports demonstrating similar distribution of malignancies at excess risk among other immune impaired populations [30,31,32 & ]. Furthermore, immunosuppression, as measured by declines in CD4 þ cell counts, is linked to a higher risk of not only classical AIDS-defining cancers but also of infectionunrelated cancers [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] .
In the light of new evidence, however, this view may be too simplistic. Recent randomized data indicate that cART reduces risk of Kaposi sarcoma and NHL also during early HIV infection before the development of overt immunosuppression [46 && ]. This benefit is measurable in the short term and reported in one trial with relatively short follow-up [46 && ]. The long-term effect of cART exposure on cancer risk, however, is not well defined, and some cohort studies have demonstrated an independent link between long-term cART exposure and cancer risk [16, 17 && ,18 & ,47]. Taken together, these findings point out a more complex and nuanced relationship between cART exposure and cancer risk than previously thought.
Here, we set out to review the newest research about the effects of cART on cancer risk in the setting of HIV infection. PubMed was searched with the terms 'HIV', 'cancer', 'AIDS', 'cART' and 'antiretrovirals' together with generic and brand names for the most commonly used antiretrovirals. Recent reports from the last 2 years were prioritized although seminal papers are referred to irrespective of publication date. Relevant reviews and abstracts presented at conferences, but not yet published, are also discussed. Whenever available, randomized data had precedence over cohort studies to support our statements.
HOW TO BEST CATEGORIZE MALIGNANCIES?
Studying associations between cART exposure and cancer risk is complicated by the relatively rare occurrence of cancer events. Although studies should ideally look into individual cancer types, grouping malignancies in broader categories may be inevitable to have power enough to detect small differences in risk. This is particularly the case for clinical trials in which follow up usually do not exceed a couple of years.
The classical categorization of malignancies into AIDS-defining and non-AIDS-defining malignancies was first introduced in the early 1990s for surveillance purposes [48] . The diagnosis of an AIDSdefining malignancy was an indicator of progression to AIDS, thus prompting HIV testing and treatment initiation. Drawbacks of this classification were subsequently made evident by the fact that malignancies not included in the classification of AIDS-defining also disproportionally affect HIVþ persons [2, [5] [6] [7] 42] .
Epidemiological surveillance has demonstrated that HIV infection and other immunosuppression states increase the risk of malignancies associated with viral and bacterial coinfections [1] [2] [3] [4] [5] [6] [7] [8] 9 && ]. As a result, the classification of cancer into infectionrelated and infection-unrelated malignancies has been an emerging trend in HIV research [49, 50 && ]. As pointed out by others [51] , this classification is not perfect because, even when considering a given cancer type such as NHL, an infectious origin can only be ascertained in a subset of cases. This classification can only be definitive after a thorough search for pathogens in tissue samples using in-situ hybridization [52, 53] . Despite these difficulties, classifying malignancies into infection-related and
KEY POINTS
HIVþ persons are at increased risk of cancer when compared with the general population. Epidemiological surveillance has demonstrated that HIV infection and other immunosuppression states increase the risk of malignancies associated with viral and bacterial coinfections.
Studying associations between cART exposure and cancer risk is complicated by the relatively rare occurrence of cancer events. Classifying malignancies into infection-related and infection-unrelated is more appropriate than into AIDS-defining and non-AIDSdefining. This classification takes into account the evolving new data from epidemiological surveillance and establishes a framework to study the interplay between HIV, bacterial and viral coinfections and cancer.
In the setting of overt immunosuppression, the benefit of cART initiation in reducing cancer risk seems to be largely mediated by suppression of HIV replication and immune function recovery. However, cART also reduces cancer risk when initiated among HIVþ persons with early HIV infection and CD4 þ cell counts above 500 cells/ml.
It is an intriguing fact that, whether initiated during severe immunosuppression or not, cART has a measurable effect on the risk of the same infectionrelated malignancies, namely Kaposi sarcoma and nonHodgkin lymphoma.
The long-term effect of cART exposure on cancer risk is not well defined. Some cohort studies have demonstrated an independent link between long-term cART exposure and cancer risk. Reported associations between protease inhibitor exposure and anal cancer warrant further investigation.
Further research is needed to identify mediators of the benefit of immediate cART initiation in reducing cancer risk, to better understand the relationship between longterm exposure to cART and cancer incidence, and to assess whether adjuvant anti-inflammatory therapies can further reduce cancer risk during treated HIV infection.
infection-unrelated seems to us more appropriate than into AIDS-defining and non-AIDS-defining. It takes into account the evolving new data from epidemiological surveillance and establishes a framework to study the interplay between HIV, bacterial and viral coinfections and cancer. However, published reports continue to use either classification indiscriminately. Not surprisingly, this makes comparisons across studies difficult.
DOES COMBINATION ANTIRETROVIRAL THERAPY REDUCE CANCER RISK?
COHORT DATA Soon after the advent of cART, observational studies have detected a major reduction in the incidence of Kaposi sarcoma and NHL following cART initiation among treatment naïve HIVþ persons [24] [25] [26] [27] . cART initiation, however, was not universally recommended. cART was to be postponed until significant declines in CD4 þ cell counts occurred, but there was no agreement among guidelines as to the CD4
þ threshold below which cART should be initiated [28, 29] . The benefit of cART in reducing cancer risk would be explained by suppression of HIV replication, immune function improvement or reduction of inflammation. The majority of studies [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] , but not all [26, 54, 55] , also pointed out a decreased incidence of malignancies not driven by infection with increased cART exposure. Therefore, global improvement of immune surveillance against cancer cells was also postulated as a likely mediator of cART benefit in reducing cancer risk [49] .
However, experimental data suggest that specific antiretrovirals and drug classes may have potential carcinogenic effects [56, 57] . This could give opportunity for cancer to develop during the prolonged lifespan brought about by cART initiation. There is now a wide range of cART regimens which physicians and HIVþ persons initiating treatment can choose from [58] [59] [60] [61] . According to basic and epidemiological research, there might be specific associations of each cART class with distinct patterns of cancer risk.
Nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimens were associated with increased risk of non-AIDS-defining cancers and Hodgkin lymphoma in one study [62] . This finding, however, was not replicated in other cohorts [16, 17 && ]. Indeed, cell culture studies identified a potential antineoplastic effect of efavirenz [63] . This is an example of how basic and epidemiological research has reached discrepant conclusions about the effects of cART exposure on cancer risk. Inherent study design limitations, different methodological approaches, variable follow-up time and distinct categorizations of malignancies are likely explanations for discrepant findings.
In animal studies, protease inhibitors were found to have a potent antiangiogenic effect and to induce regression of Kaposi sarcoma [64, 65] . It was expected, in clinical practice, that protease inhibitor-based cART would reduce the incidence of Kaposi sarcoma more than other cART regimens. However, NNRTIbased and protease inhibitor-based regimens were equally effective in reducing incidence of Kaposi sarcoma in cohort studies [66, 67] . A recent trial involving cART naïve patients with Kaposi sarcoma compared protease inhibitor-based with NNRTIbased cART for a composite endpoint of death or requirement for systemic chemotherapy [68 & ].
Protease inhibitor-based regimens were not superior to NNRTI-based cART. Therefore, despite strong biological plausibility [64, 65] , regression of Kaposi sarcoma after cART initiation cannot be attributable to the effects of specific antiretrovirals.
In epidemiological studies, protease inhibitorbased regimens were independently associated with increased risk of anal cancer. This finding was replicated in at least three different cohorts [16, 17 &&
It is important to monitor this association because the incidence of anal cancer is increasing significantly among HIVþ persons [6, 69] . As for a composite endpoint of non-AIDS-defining cancers, an increased risk was observed with cumulative exposure to protease inhibitor-based cART in one study [17 && ] but not in other [16] . No clear pathophysiological mechanism has been proposed to explain this possible association. From our studies, protease inhibitor-based regimens were linked to higher levels of IL-6 [70] , a cytokine involved in all stages of cancer development [71] . Elevated plasma levels of IL-6 and other biomarkers of activated inflammation and coagulation were linked to future risk of both infection-related and infection-unrelated malignancies among HIVþ persons [19] [20] [21] 23 ]. In one randomized trial, participants switching away from protease inhibitorbased regimens experienced significant reductions in IL-6 levels when compared with participants continuously receiving protease inhibitors [72] .
Integrase inhibitors and C-C chemokine receptor type 5 (CCR5) inhibitors have only recently been used in clinical practice. As a result, most HIV cohorts have not had enough follow-up time to study associations between the new drugs and rare clinical outcomes such as cancer. DNA rearrangements caused by integrase inhibitors could potentially lead to an increased risk of cancer [73] . A recent cohort study compared cancer incidence between participants receiving or not raltegravirbased regimens [74 was observed. CCR5 inhibition can potentially reduce immune surveillance of malignant cells; in one trial involving treatment experienced participants, four of 90 vicriviroc recipients and none of 28 control subjects developed lymphoma [75] . This signal, however, has not been confirmed by other studies and vicriviroc treatment seems to have no effect on Epstein-Bar virus (EBV) reactivation [76] . & ]. However, one study found that cART-treated persons with CD4 þ cell counts above 300 cells/ml who developed Kaposi sarcoma had a longer survival than those diagnosed with Kaposi sarcoma at lower CD4 þ cell counts [84] . The impact of cART initiation on the risk of infection-unrelated or non-AIDS-defining cancer is more difficult to quantify because there are few randomized trials reporting these cancer events among HIVþ persons initiating treatment (Fig. 1) . (Fig. 1) . This risk reduction is not significant most probably because the short follow-up of trials did not give enough opportunity for less common malignancies to develop. Indeed, we found no statistical significance when we tested the difference in hazard ratios for infection-related versus infection-unrelated cancer in START (P ¼ 0.27) [46 && ]. Another informative trial for the debate on how cART use influences cancer risk was the Strategies for Management of Antiretroviral Therapy (SMART) study [88] . SMART compared, in individuals with CD4 þ cell count above 350 cells/ml at baseline, continuous cART use (viral suppression arm) versus structured cART interruptions guided by CD4 þ cell counts (drug conservation arm). Structured treatment interruptions were associated with a significantly higher risk of AIDS-defining malignancies (hazard ratio drug conservation/viral suppression; 95% CI: 5.5; 1.2-25.0; P ¼ 0.03). No significant effect on the risk of non-AIDS-defining cancer was observed (hazard ratio drug conservation/viral suppression; 95% CI: 1.3; 0.7-2.1; P ¼ 0.40) [89] . However, given the low numbers of cancer events, a modest effect of cART interruption on the risk of non-AIDS-defining cancer could not be entirely excluded as demonstrated by the upper limit of CI. An individual participant data analysis combining SMART and START will be helpful to quantify accurately the impact of immediate and continuous cART, the strategy recommended by current treatment guidelines, on cancer risk.
RANDOMIZED DATA

Study or subgroup
HOW DOES COMBINATION ANTIRETROVIRAL THERAPY REDUCE CANCER RISK?
In the setting of overt immunosuppression, the benefit of cART initiation in reducing cancer risk seems to be largely mediated by suppression of HIV replication and immune function recovery. This is corroborated by the fact that persons with persistent declines in CD4 þ cell counts or with suboptimal immune recovery following cART initiation continue at increased risk of cancer [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] . However, cART also reduces cancer risk when initiated among HIVþ persons with early HIV infection and CD4 þ cell counts above 500 cells/ml [46 && ]. It is an intriguing fact that, whether initiated during severe immunosuppression or not, cART has a measurable effect on the risk of the same infection-related malignancies, namely Kaposi sarcoma and NHL. This calls for a better understanding of the mechanisms by which cART lowers cancer risk among persons with high CD4 þ cell counts. Contrary to what we hypothesized, adjustment for CD4 þ cell counts had no impact on the protective effect of immediate cART on cancer risk among START participants and adjustment for HIV RNA levels only partially attenuated this association [46 && ]. Though limited by a small sample size and a relatively short follow-up, our findings suggest that benefit of immediate cART doesn't appear to be solely attributable to HIV RNA suppression and may also be mediated by other mechanisms, such as a curb on oncogenic virus coinfection and reduction of inflammation.
Recent data suggest that HIV may be directly involved in lymphomagenesis [90, 91] . HIV-derived p17 secreted within lymphoid tissues promotes microenvironment changes that may foster lymphoma development [90] . Sequencing studies have demonstrated that HIV isolated from lymphoma tissue is genetically distinct from HIV present in normal tissues [92] . Upon cancer diagnosis and metastasis, the genetic diversity of HIV may be increased within cancer tissues [93] . Furthermore, in some studies, HIV RNA levels were associated with subsequent development of lymphomas [94, 95] . It is possible that cART reduces lymphoma risk by directly interfering with HIV-associated lymphomagenesis. As EBV latency patterns observed in NHL tissue differs between pre-cART [96] and postcART studies [97] , it was also hypothesized that cART may improve immune surveillance of proteins expressed by cells latently infected by EBV resulting in a shift to a less oncogenic latency pattern [97] .
It is unclear how cART interferes with mechanisms promoting carcinogenesis in HIVþ persons with high CD4 þ cell counts. Elevated levels of biomarkers are associated with increased risk of infection-related and infection-unrelated cancer [19] [20] [21] [22] [23] . Thus, reduction of inflammation could be an important mechanism explaining the lower risk of cancer observed after cART initiation. However, cART does not entirely normalize the enhanced inflammation and hypercoagulation state characteristic of HIV disease [98] [99] [100] . This raises the question as to whether adjuvant anti-inflammatory therapies could further reduce cancer risk among cART-treated HIVþ persons. Observational studies have reported a lower cancer risk among HIVþ persons receiving statins [101] [102] [103] [104] . The evaluating the use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults (REPRIEVE) trial will randomize 6500 HIVþ individuals to start statins or placebo [105] . REPRIEVE has cardiovascular disease as the primary endpoint but may also provide an opportunity to investigate the effect of statins on cancer incidence during treated HIV infection.
CONCLUSION
The relationship between cART exposure and cancer risk is complex and nuanced. Recent randomized data indicate that immediate cART initiation reduces risk of Kaposi sarcoma and NHL during early HIV infection before the development of overt immunosuppression. The long-term effect of cART exposure on cancer risk, however, is not well defined and some cohort studies have demonstrated an independent link between protease inhibitor exposure and risk of anal cancer. Further research should identify mediators of the benefit of immediate cART initiation in reducing cancer risk, understand the relationship between long-term cART exposure and cancer incidence, and assess whether adjuvant anti-inflammatory therapies can reduce cancer risk during treated HIV infection. 
